Dr. Charles Lynde is a recognized figure in Canadian dermatology and recipient of the Award of Merit by the Canadian Dermatology Association. He is the director of the Dermatology Update conference, medical director of Lynde Dermatology and Lynderm Research, and has authored over 150 articles, and is a regular contributor to SkinTherapyLetter. His research interests include psoriasis, acne, psoriatic arthritis, as well as cosmetic dermatology.
STL Index for: Charles W. Lynde
Peri-procedural measures in dermato-surgery depend on patient factors and procedure type. Standardized guidelines support healthcare providers in optimizing outcomes, preventing infection, and reducing recovery time. Research is needed to evaluate purpose-designed moisturizers for post-procedural application and improving patient outcomes.
Casmo Algorithm for Management of Hormonal Therapy-Related Cutaneous Adverse Effects in Oncology Patients
Breast and prostate cancer patients frequently use hormonal therapy to improve treatment outcomes and survival. However, these medications can be associated with numerous dermatologic adverse effects.
Results from multiple studies have shown promising response rates, and extracorporeal photopheresis has an overall excellent safety profile with very few adverse events reported.
CaSMO Management of Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: A Practical Primer
The management of cirAEs starts with physician awareness and patient education on the occurrence of toxicities, preventive measures, and skincare using gentle cleansers, moisturizers, and sunscreen started before immunotherapy begins and ongoing thereafter as part of the lifestyle.
Canadian Skin Management in Oncology Group (Casmo) Algorithm for the Prevention and Management of Acute Radiation Dermatitis
The Canadian Skin Management in Oncology Group (CaSMO) developed an algorithm for the reduction of severity and management of acute RD, which follows previous publications from this group that addressed general oncology-treatment related cutaneous adverse events [AEs], prevention, and skin management.
Mild to moderate atopic dermatitis (AD) is often controlled by behavioral measures such as skincare and avoidance of triggers in addition to topical treatments such as topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), and crisaborole, a phosphodiesterase-4 inhibitor (PDE4-I).
Moisturizers and Cleansers in the Management of Skin Conditions Caused by Personal Protective Equipment and Frequent Handwashing
Routine moisturization with non-irritating, pH-adjusted, ceramide-based products and gentle cleansing with a pH-adjusted cleanser can treat the unique dermatological challenges posed by COVID-19.
Novel therapeutics are currently being explored for the treatment of Prurigo Nodularis. Nemolizumab and dupilumab both demonstrate promise in inhibiting specific central nervous system pathways responsible for transmission of the pruritic sensation.
Canadian Skin Management in Oncology (CaSMO) Algorithm for Patients with Oncology Treatment-Related Skin Toxicities
The CaSMO (Canadian Skin Management in Oncology) algorithm focuses on general skincare measures to prevent or reduce the severity of cancer-treatment-related cutaneous toxicities.
The discussed cases reflect the panels’ real-world clinical experience with crisaborole for the treatment of patients with AD and the off-label treatment of irritant dermatitis.
Evolving understanding of the role of hormones in acne, along with a growing body of data from clinical trials, calls for a reappraisal of the role of hormonal therapy for acne.
Urticaria is a common, mast-cell-driven disease, characterized clinically by the development of wheals, angioedema, or both. A large body of data has demonstrated that omalizumab, a biologic agent, is safe and effective in the treatment of H1- antihistamine refractory urticaria and should be considered as a third-line agent, with cyclosporin A reserved for fourth-line therapy.
A group of dermatologists with extensive experience in managing pediatric and adult patients with atopic dermatitis developed practical recommendations for the management of atopic dermatitis based on expert consensus opinion and the best available medical evidence.
Practical guidelines for the management of Chronic Hand Dermatitis were published in the Skin Therapy Letter, Family Practice Edition (October 2016). This series of cases using Alitretinoin (Toctino®), is a follow on to that publication to put the guidelines into context.
Tofacitinib is an oral immunosuppressant approved for the treatment of rheumatoid arthritis (RA) and is currently undergoing investigation (Phase III trials) for treating chronic plaque psoriasis.
Hand Dermatitis can have a significant impact on quality of life. It may interfere with activities both at work and in the home and can be associated with social and psychological distress. This article provides helpful practical guidance for the general practitioner in the management of patients with Hand Dermatitis.
Genetic predisposition to melanoma and nonmelanoma skin cancer extends far beyond the Fitzpatrick phenotype classification scheme. Testing aimed at improving prognostication may serve to limit the influence of certain risk factors.
Atopic dermatitis (AD) or eczema is a chronic, relapsing form of skin inflammation that is attributable to multiple pathogenic, genetic, and environmental factors, as well as a dysfunctional epidermal barrier. Immune responses involved in AD culminate in dry skin, pruritus, and IgE mediated sensitization to food and environmental allergens.
This article describes how pharmacists can play an important role in providing for patients with their skin concerns and counselling patients on effective management and behavioral strategies as well as prescribing. Reactive and proactive communication approaches are described.
Hyperpigmentation disorders of the skin are common and can be the source of significant psychosocial distress for patients. Topical applications are the mainstay of treatment and include phenols, retinoids, corticosteroids, and their combinations.
Moisturizers are widely used products that are important in many dermatologic and cosmetic skin therapies. They contain varying combinations of emollients, occlusives, and humectants to achieve their beneficial effects, and there is an overwhelming number of formulations available.